Janna L. Huskey

Janna L. Huskey

Auto-generated profile, based on publicly available information

Janna L. Huskey

Division of Transplant Nephrology, Mayo Clinic, Phoenix, Arizona

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CJCaroline Jadlowiec
Caroline Jadlowiec
RHRaymond L. Heilman
Raymond L. Heilman
MSMaxwell L. Smith
Maxwell L. Smith
HKHasan A. Khamash
Hasan A. Khamash
JHJanna L. Huskey
Janna L. Huskey
AMAdyr A. Moss
Adyr A. Moss
Donation after cardiac death (DCD) and acute kidney injury (AKI) donors have historically been considered independent risk factors for delayed graft function (DGF), allograft failure, and inferior outcomes. With growing experience, updated analyses have shown good outcomes. There however continues to be limited data on outcomes specific to DCD donors who have AKI. Primary outcomes for this study were post‐kidney transplant patient and allograft survival comparing two donor groups: DCD AKIN stage 2‐3 and DBD AKIN stage 2‐3. In comparing these groups, there were no short‐ or long‐term differences in patient (HR 1.07, 95% CI 0.54‐1.93, p=0.83) or allograft survival (HR 1.47, 95% CI 0.64‐2.97, p=0.32). In multivariate models, the DCD/DBD status had no significant impact on the eGFR at 1‐ (p=0.38), 2‐ (p=0.60), and 3‐years (p=0.52). DGF (57.9% vs. 67.9%, p=0.09), rejection (12.1% vs. 13.9%, p=0.12), and progression of interstitial fibrosis/tubular atrophy (IFTA) on protocol biopsy (p=0.16) were similar between the two groups. With careful selection, good outcomes can be achieved utilizing severe AKI DCD kidneys. Historic concerns regarding primary non‐function, DGF resulting in interstitial fibrosis and rejection, and inferior outcomes were not observed. Given the ongoing organ shortage, increased effort should be undertaken to further utilize these donors.

27 February 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
KAKara Asbury
Kara Asbury
JBJanis Blair
Janis Blair
JAJessica August
Jessica August
Norman L BeattyNorman L Beatty
Norman L Beatty
LMLanyu Mi
Lanyu Mi
TZTirdad T Zangeneh
Tirdad T Zangeneh
Solid organ transplant recipients who contract coccidioidomycosis are at risk for complicated, protracted, disseminated, and severe disease. To date, no studies have described outcomes for patients who develop coccidioidomycosis only after the first posttransplant year. This study was a joint project of Mayo Clinic Hospital, Phoenix, Arizona, and the University of Arizona/Banner University Medical Center, Tucson, Arizona. We retrospectively reviewed electronic health records for patients with a history of solid organ transplant between January 1, 1998, and October 11, 2014, who developed coccidioidomycosis after the first transplant year. We identified 91 patients. Of those, 37/91 (40.7%) had pulmonary coccidioidomycosis (29/37 [78.4%] were symptomatic); and 5/91 (5.5%) had extrapulmonary disease (all were symptomatic). One patient (1.1%) died. Coccidioidomycosis was evident in 2/91 (2.2%) patients within 3 months of antirejection treatment. Many of the patients (51/91 [56.0%]) had asymptomatic coccidioidomycosis, 27 (27.9%) of whom were followed up closely but did not receive antifungal medication and had no sequelae. Although solid organ recipients taking low‐level immunosuppression after the first posttransplant year appeared to have less symptomatic, disseminated, or fatal coccidioidal infection than historical cohorts, this remains an important infection with morbidity and mortality even after the first post‐transplant year.

13 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ZYZachary A Yetmar
Zachary A Yetmar
YKYogish C. Kudva
Yogish C. Kudva
MSMaria Teresa Seville
Maria Teresa Seville
WBWendelyn Bosch
Wendelyn Bosch
JHJanna L. Huskey
Janna L. Huskey
EBElena Beam
Elena Beam